Bicycle Therapeutics
Established: 2009
Country: United Kingdom
Region: Cambridge
Investors: Cambridge Innovation Capital, SV Health Investors, Novartis Venture Fund, Longwood Fund, SR One, Vertex Ventures HC, Atlas Venture, Innovate UK, Astellas Venture Management, Syndicate Bank
Cambridge, UK-founded Bicycle Therapeutics takes its name from bicyclic peptides, a new kind of molecule that can penetrate deep into tissue to combat intractable cancers. Bicycle’s treatments target solid tumours that can be resistant to smaller molecules and provide a precision-guided approach that can spare unaffected tissue and cells.
Venture capital investment and support helped Bicycle to progress its innovative treatments through clinical trials and establish an early discovery collaboration with US biotech leader Genentech to invest in new immuno-oncology therapeutics. The company has also been identifying fields for development beyond cancer with applications in diabetes-related vision loss and dementia, as well collaborations on a variety of other solutions ongoing with AstraZeneca.
What do Bicycles have to do with Oncology? (Video – 05:54)
$147m
raised from VC and pacts with partners
$61m
raised in 2019 IPO
119
employees in 2022, doubling the size of the company
Key achievement
Successful Phase I clinical trials for first-in-class Bicycle treatments, and rapid progress for next-generation therapeutics
Funding history
Raised $147m from VC and pacts with partners1
Raised $61m in 2019 IPO, and $300m in subsequent private placements2
Employment impact
Doubled employment to 119 staff in 20223
Find out more
1. https://endpts.com/bicycle-raises-61m-in-downsized-ipo-joining-fellow-biotechs-on-nasdaq-who-have-hauled-in-1-6b-collectively/
2. Preqin
3. https://www.macrotrends.net/stocks/charts/BCYC/bicycle-therapeutics/number-of-employees
Investors
